Statins and Risk of Rheumatoid Arthritis: A Nested Case–Control Study

Arthritis and Rheumatology

Volumn 68, Issue 11, 2016, Pages 2603-2611

  Tascilar, Koray ^a,b   Dell'Aniello, Sophie ^a   Hudson, Marie ^a   Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMOKING; AGED; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; DYSLIPIDEMIAS; HYPOTHYROIDISM; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODEL; PROTECTION; STATISTICAL MODEL; UNITED KINGDOM;

AGED; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOTHYROIDISM; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RISK FACTORS; SMOKING; UNITED KINGDOM;

EID: 84992648197     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39774     Document Type: Article

References (32)

1. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013:CD004816.
2. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640–51.
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–207.
4. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015–21.
5. Forero-Pena DA, Gutierrez FR. Statins as modulators of regulatory T-cell biology. Mediators Inflamm 2013;2013:167086.
6. De Jong HJ, Damoiseaux JG, Vandebriel RJ, Souverein PC, Gremmer ER, Wolfs M, et al. Statin use and markers of immunity in the Doetinchem cohort study. PLoS One 2013;8:e77587.
7. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009;68:546–51.
8. De Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012;71:648–54.
9. Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010;7:e1000336.
10. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99–109.
11. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
12. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051–7.
13. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011;26:546–50.
14. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139–51.
15. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003;4:18.
16. Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf 2013;22:1298–307.
17. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006;35:169–74.
18. Lahiri M, Morgan C, Symmons DP, Bruce IN. Modifiable risk factors for RA: prevention, better than cure? Rheumatology (Oxford) 2012;51:499–512.
19. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
20. Suissa S. The quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. Epidemiology 2015;26:242–6.
21. Nicholson A, Ford E, Davies KA, Smith HE, Rait G, Tate AR, et al. Optimising use of electronic health records to describe the presentation of rheumatoid arthritis in primary care: a strategy for developing code lists. PLoS One 2013;8:e54878.
22. Wiles N, Symmons DP, Harrison B, Barrett E, Barrett JH, Scott DG, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999;42:1339–46.
23. Patrick AR, Shrank WH, Glynn RJ, Solomon DH, Dormuth CR, Avorn J, et al. The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adults. Value Health 2011;14:513–20.
24. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006;59:819–28.
25. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001;12:682–9.
26. Ulivieri C, Baldari CT. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol Res 2014;88:41–52.
27. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358–70.
28. Dusetzina SB, Brookhart MA, Maciejewski ML. Control outcomes and exposures for improving internal validity of nonrandomized studies. Health Serv Res 2015;50:1432–51.
29. Schmidt T, Battafarano DF, Mortensen EM, Frei CR, Mansi I. Frequency of development of connective tissue disease in statin-users versus nonusers. Am J Cardiol 2013;112:883–8.
30. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum 2008;59:1314–21.
31. Mainous AG III, Baker R, Everett CJ, King DE. Impact of a policy allowing for over-the-counter statins. Qual Prim Care 2010;18:301–6.
32. Van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013;72:1920–6.